Laboratory of Clinical Investigation |
Intramural Program Investigators ^ Home ^ |
Josephine M. Egan, M.D., Senior Investigator Chief, Diabetes Section |
![]() Research Interests: Type 2 diabetes mellitus and the identification of new targets for its treatment are the focus of this Section as it relates to drug discovery and development. Dr. Egan has identified the GLP-1 receptor as a promising target as an insulinotropic agent. In the past Dr. Egan has shown in preclinical and clinical study that the GLP-1 receptor ligand exendin-4 may provide a new approach for the treatment of Type II diabetes mellitus. This work has provided the scientific basis, both preclinical and clinical, that has made this therapeutic target and drug attractive to the private sector, where it is now in later stages of clinical development. The present focus is the study of the mechanisms of the release of enteric peptides that modulate insulin release, and an in-depth study of one of the peptides, GIP, and its receptor, to further understand the role of insulinotropic treatments for type 2 diabetes mellitus. |
Contact Information: Laboratory of Clinical Investigation Biomedical Research Center, room 09B133 251 Bayview Boulevard, Suite 100 Baltimore, MD 21224-6825 Phone 410-558-8414 Fax 410-558-8381 E mail eganj@grc.nia.nih.gov For more information about the Laboratory: http://www.grc.nia.nih.gov/branches/lci/diabetes/diabetes.htm |
IRP Home What's New Contact Us Accessibility Disclaimer Privacy Site Search Site Map NIA Home |
![]() |
![]() |
![]() |